Breast cancer is highly heterogenous and has various subtypes, thus it is destined to be a complicated disease to treat, especially triple negative breast cancer (TNBC) which lacks the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (3). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.